department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Azmiro · pharmadog

pharmadog
drugs
Azmiro

drug

patient view →

Azmiro

Marketedupdated 2mo ago

by Slayback Pharma LLC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Azmiro

generic

testosterone cypionate

indication

Secondary (Hypogonadotropic) Hypogonadism

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 25, 2039

~12.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Mar 25, 2039formulationUS 11311554
Mar 25, 2039formulationUS 11642355
Mar 25, 2039formulationUS 12138271

Data sources

ClinicalTrials.gov

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 7

tagRecall3 co-mentions · 3 sources
drugtestosterone3 co-mentions · 3 sources
drugtestosterone cypionate3 co-mentions · 3 sources
drugTestim3 co-mentions · 3 sources
drugVogelxo3 co-mentions · 3 sources
drugBio T3 co-mentions · 3 sources
companyEugia US LLC2 co-mentions · 1 sources

Trials studying Azmiro

phase2Supraphysiologic Testosterone Priming Induces Darolutamide Extended Responserecruitingn=60
phase2Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)active not recruitingn=51
phase2Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancerrecruitingn=50
phase4Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Mennot yet recruitingn=144
phase2Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCrecruitingn=26
phase2Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancercompletedn=36
phase2The COSMYC Trial (COmbined Suppression of MYC)recruitingn=50
phase2COMbination of Bipolar Androgen Therapy and Nivolumabcompletedn=45

more trials →